Introduction
============

Testicular germ cell tumors (TGCTs) belong to the most common malignancies among men aged between 20--40 years ([@b1-ol-0-0-5745],[@b2-ol-0-0-5745]). TGCTs are highly curable malignancies and even the majority of metastatic patients may expect to be cured with the first-line cisplatin-based chemotherapy ([@b3-ol-0-0-5745],[@b4-ol-0-0-5745]). Despite the high curative rate, there are \~20--30% of patients who fail to achieve a durable complete remission ([@b3-ol-0-0-5745]). Salvage chemotherapy based on the standard cisplatin dose and previously non-utilized chemotherapeutic agents or high-dose salvage chemotherapy with autologous stem cell transplantation can induce durable remission in 20--60% of patients with relapsed disease ([@b3-ol-0-0-5745],[@b5-ol-0-0-5745],[@b6-ol-0-0-5745]). Current treatment strategies in cisplatin-refractory and relapsed TGCTs patients are insufficient. Thus, novel treatment strategies, including drugs with antitumor activity, as well as novel biomarkers as effective tools for better stratification of patients are required.

The process of tumor development is characterized by rapid proliferation of cancer cells and the expansion of tumor tissue associated with hypoxia in the tumor microenvironment ([@b7-ol-0-0-5745]). Carbonic anhydrase IX (CA IX) is a zinc metalloenzyme, which catalyzes a reversible hydration of carbon dioxide to bicarbonate and a proton, and participates in pH regulation, in addition to cell adhesion-migration-invasion ([@b8-ol-0-0-5745]). Thus, CA IX, localized in the plasma membrane, enables tumor cells to maintain a normal intracellular pH under hypoxic conditions, while concurrently acidifying the extracellular microenvironment. The increased expression of CA IX promotes invasion and metastasis and is associated with treatment resistance in several types of cancer ([@b9-ol-0-0-5745]--[@b12-ol-0-0-5745]). Hypoxia and CA IX have been also linked with cancer stem cell properties ([@b13-ol-0-0-5745]--[@b15-ol-0-0-5745]). Furthermore, inhibition of angiogenesis is able to generate a hypoxic tumor microenvironment, thereby increasing the population of breast cancer stem cells ([@b16-ol-0-0-5745]). Thus, an increased proportion of circulating tumor cells derived from tumors that grow under hypoxic conditions may contribute to a poor treatment outcome and increased resistance to chemotherapy ([@b17-ol-0-0-5745]). Since cancer stem cells in TGCTs resemble embryonic stem cells ([@b9-ol-0-0-5745],[@b18-ol-0-0-5745]), we propose that CA IX, as a mediator of tumor responses to hypoxia, may be involved in the pathogenesis of TGCTs.

The aim of the present translational study was to investigate the CA IX protein expression in TGCTs and to evaluate its potential prognostic role in these patients. We examined the CA IX expression in all histological subtypes of TGCTs, as well as in GCNIS (germ cell neoplasia *in situ*) specimens and in the normal testicular tissue adjacent to testicular tumor.

Patients and methods
====================

### Patients

The present translational study (Protocol IZLO1, Chair: M. Mego) involved 228 patients with TGCTs treated from January 2000 to September 2013 in the National Cancer Institute of Slovakia, Bratislava, Slovakia and St. Elisabeth Cancer Institute, Bratislava, Slovakia, with available paraffin embedded tumor tissue specimen and sufficient follow-up clinical data. Patients with a concurrent malignancy other than non-melanoma skin cancer in the previous 5 years were excluded from the study. In all patients, data regarding age, tumor histological subtype, clinical stage and type and number of metastatic lesions were recorded and compared with the CA IX expression. The Institutional Review Board of the National Cancer Institute, Bratislava, Slovakia approved this retrospective study and a waiver of patient consent was granted.

### Tumor pathology

Pathological review was conducted at the Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia by two pathologists (Z.C. and P.B.) associated with the study.

### Diagnosis and tissue samples

Tumor tissue, samples with germ cell neoplasias *in situ* (GCNIS), and normal testicular tissue were evaluated in all cases, when available. The present study included tumor specimens from 228 patients prior to the administration of systemic therapy. Primary testicular tumor specimens were obtained in 205 (89.9%) patients. Biopsies of metastatic sites were available in 23 (10.1%) cases.

The TGCTs were classified according to the World Health Organization criteria ([@b19-ol-0-0-5745]). Since the normal testicular biopsies from non-cancer patients were not available for our analysis, normal tissue adjacent to testicular tumor was used for evaluation of CA IX expression, as described in previous studies ([@b20-ol-0-0-5745]--[@b22-ol-0-0-5745]).

### Tissue microarray construction

According to tumor histology, one or two representative tumor areas from each histological subtype of germ cell tumor (from 1--6 cores from each tumor) were identified on haematoxylin and eosin stained sections. Samples from normal testicular tissue and germ cell neoplasia *in situ* were also marked, if present. Sections were matched to their corresponding wax blocks (the donor blocks), and 3-mm diameter cores of the tumor were removed from these donor blocks with the multipurpose sampling tool Harris Uni-Core (Sigma-Aldrich, Steinheim, Germany) and inserted into the recipient master block. The recipient block was cut into 5-µm sections that were transferred to coated slides.

### Immunohistochemical staining

Deparaffinized slides were rehydrated in phosphate buffered saline solution (10 mM, pH 7.2). The tissue epitopes were demasked using the automated water bath heating process in Dako PT Link (Dako, Glostrup, Denmark); the slides were incubated in TRIS-EDTA retrieval solution (10 mM TRIS, 1 mM EDTA pH 9.0) at 98°C for 20 min. This step was introduced because of low intensity of staining when the standard CA IX immunohistochemical staining protocol was used ([@b23-ol-0-0-5745]). Increasing the concentration, nor the extension of incubation time with the M75 primary antibody, did improve the staining result, however, pretreatment with TRIS-EDTA substantially strengthened the reaction signal. The slides were subsequently incubated for 1 h at room temperature with the monoclonal antibody M75 against the N-terminal domain of the human CA IX protein ([@b23-ol-0-0-5745],[@b24-ol-0-0-5745]) diluted 1:100 in Dako REAL antibody diluent (Dako, Glostrup, Denmark) and immunostained using anti-mouse/anti-rabbit immune-peroxidase polymer (EnVision FLEX/HRP, Dako, Glostrup, Denmark) for 30 min at room temperature, according to the manufacturer\'s instructions. The reaction was visualized with a diaminobenzidine substrate-chromogen solution (DAB, Dako Cytomation, Denmark) for 5 min, and slides were counter-stained with haematoxylin. The trophoblast staining in human placenta served as positive control. Additional testicular tumors specimens stained with omission of the primary antibody served as negative control.

### Immunohistochemistry scoring

Two observes (Z.C. and P.B.) who were blinded to clinicopathological data conducted an independent analysis of the tumor cores. In cases of disagreement, the result was reached by consensus. CA IX expression was stratified as negative or positive (any staining).

### Statistical analysis

The patients\' characteristics were summarized as mean or median (range) values for continuous variables and frequency (percentage) for categorical variables, respectively. Statistical analysis was performed using non-parametric tests as the distribution of the CA IX expression was significantly different from the normal distribution (Shapiro-Wilk test). Analyses of differences in distributions of CA IX expression between the two groups of patients were performed using the Mann-Whitney U test, whereas Fisher\'s exact test or the χ^2^ test were used when CA IX expression was categorized as 'absent' or 'present' according to the aforementioned criteria. Median follow-up period was calculated as a median observation time of all patients and of those still alive at the time of their last follow-up. Progression-free survival (PFS) was calculated from the date of the starting treatment with systemic therapy to the date of progression or death or the date of the last adequate follow-up. Overall survival (OS) was calculated from the date of starting treatment with systemic therapy to the date of death or last follow-up. PFS and OS were estimated using the Kaplan-Meier product limit method and were compared with the log-rank test. A multivariate Cox proportional hazards model for PFS and OS was used to assess differences in outcome on the basis of the CA IX expression in primary tumor and/or biopsy of metastatic site and prognosis according to the IGCCCG (International Germ Cell Collaborative Group) criteria (1997) ([@b19-ol-0-0-5745]). All presented P-values were two sided. Values of P\<0.05 were considered to indicate a statistically significant difference. Statistical analyses were performed using NCSS 2007 software developed by Hintze J (2007) (NCSS, LLC, Kaysville, UT, USA) ([@b25-ol-0-0-5745]).

Results
=======

### Patient characteristics

Patients characteristics are summarized in [Table I](#tI-ol-0-0-5745){ref-type="table"}. The mean age of patients enrolled into this study was 30 years (range, 16--67 years). The majority of patients had non-seminomatous primary testicular tumor, and had good prognosis according to the IGCCCG criteria. All patients were treated with cisplatin-based chemotherapy. No extragonadal germ cell tumors were included.

In total, 228 patient specimens were analyzed for CA IX expression using immunohistochemical analysis. CA IX staining was evaluated in 321 tumor specimens from primary testicular tumors (205 patients, [Table II](#tII-ol-0-0-5745){ref-type="table"}), in 23 specimens from metastatic sites sampled post chemotherapy, and in 107 adjacent normal testicular tissues. GCNIS adjacent to testicular tumor was present in 76 patients.

The analyzed cohort of primary testicular tumors included 49 pure seminomas, 79 non-seminomas (57 embryonal carcinomas, 12 yolk sac tumors, 9 teratomas, 1 choriocarcinoma) and 76 mixed germ cell tumors ([Table III](#tIII-ol-0-0-5745){ref-type="table"}). Six cases of seminomas were clinically considered as non-seminomas based on positivity of alpha-fetoprotein.

### Association between CA IX expression and patients/tumor characteristics

CA IX staining of various TGCTs histological subtypes and normal tissue adjacent to testicular tumor is presented in [Fig. 1](#f1-ol-0-0-5745){ref-type="fig"}. Whereas normal testicular tissue adjacent to testicular tumor did not show any CA IX staining, CA IX expression was detected in all histological subtypes of TGCTs ([Table II](#tII-ol-0-0-5745){ref-type="table"}). The highest frequency of the CA IX expression was in teratoma samples, with decreasing trend in seminoma, embryonal carcinoma, yolk sac tumor and choriocarcinoma. In choriocarcinomas, the CA IX staining was observed only in one (7.7%) specimen, while no CA IX expression was observed in GCNIS. CA IX expression was detected in 17 seminomas (22.7), 14 embryonal carcinomas (11.9), 8 yolk sac tumors (22.2) and 23 teratomas (39.0) compared to 0 (0.0) of normal testicular tissue adjacent to testicular tumor (P\<0.001; [Table II](#tII-ol-0-0-5745){ref-type="table"}).

The CA IX staining pattern was largely focal in the tumor tissue, with prevailing membrane positivity in seminomas and embryonal carcinomas and cytoplasmic staining in the other histological subtypes. Mesenchymal cells in teratomas and in the tumor stroma exhibited focal positivity, the intercellular matrix was negative ([Fig. 1](#f1-ol-0-0-5745){ref-type="fig"}). Areas of cells neighboring with necrosis did not show increased CA IX expression.

In addition, we analyzed the relationship between the CA IX expression in primary tumors and clinicopathological features ([Table IV](#tIV-ol-0-0-5745){ref-type="table"}). We did not find any significant association of the CA IX expression in primary tumors with patients/tumor characteristic, such as tumor histology, IGCCCG risk group, number and localization of metastatic sites and S-stage ([Table V](#tV-ol-0-0-5745){ref-type="table"}). The Spearman\'s test did not show any significant correlation between the intratumoral CA IX expression and LDH level (Spearman\'s correlation index, P=0.216).

### Prognostic value of CA IX

The median follow-up time was 82.3 months (0.3--289.1 months) for all 228 patients and 92.6 months (14.2--289.1 months) for patients still alive. To the date of last follow-up, 56 patients (24.6%) experienced disease progression and 38 patients (16.7%) had succumbed. The estimated 2-year and 5-year PFS survival was 80.3% (95% CI, 75.1--85.4%) and 78.3% (95% CI, 72.9--83.7%), while the estimated 2-year and 5-year OS survival was 90.3% (95% CI, 86.5--94.2%) and 85.1% (95% CI, 80.4--89.8%), respectively.

In univariate analysis, patients without CA IX expression in analyzed tumor specimens had significantly better PFS, in contrast to patients with the CA IX expression \[hazard ratio (HR), 0.57; 95% CI, 0.32--1.02; P=0.0365; [Fig. 2](#f2-ol-0-0-5745){ref-type="fig"}\]. Moreover, there was a trend for association between the CA IX expression and OS in this patients\' cohort (HR, 0.58; 95% CI, 0.29--1.16; P=0.0876; [Fig. 3](#f3-ol-0-0-5745){ref-type="fig"}). Multivariate analysis revealed that CA IX expression in tumor tissues was associated with PFS independently of the IGCCCG risk group, however this correlation did not reach statistical significance (P=0.0682). Moreover, no significant association was shown between the IGCCCG risk group and the CA IX expression as an independent prognostic factor for overall survival ([Table V](#tV-ol-0-0-5745){ref-type="table"}).

Therefore, exploratory subgroup analysis was performed to reveal a potential subgroup-related prognostic value of CA IX ([Table VI](#tVI-ol-0-0-5745){ref-type="table"}). This analysis demonstrated that the tumor CA IX expression correlated with the worse PFS in non-seminoma patients, patients with one or more metastatic lesions and patients with retroperitoneal lymph node metastases. Furthermore, the absence of the CA IX expression in primary tumors was significantly associated with better PFS in patients without lung, brain and non-pulmonary visceral metastases.

Discussion
==========

Carbonic anhydrase IX (CA IX) is a hypoxia-inducible enzyme that is important in cancer development, progression, acidification and metastasis ([@b8-ol-0-0-5745]). There is increasing evidence that overexpression of CA IX in a variety of cancers correlates with an unfavorable outcome, and is related to a decrease in the progression free survival following successful therapy. Therefore, it is considered as a surrogate tumor biomarker ([@b26-ol-0-0-5745]).

The present translational study demonstrated significantly increased CA IX expression in TGCTs, in contrast to its absence in normal testicular tissue adjacent to germ cell tumors. CA IX expression was demonstrated in all histological subtypes, with the highest expression in teratomas. These findings can be explained by the mesodermal origin of all CA IX expressing cells. Moreover, our results are supported by the detection of CA IX expression in the flat surface epithelium (modified mesothelium) of all male and female genital organs ([@b27-ol-0-0-5745]). Only one of thirteen choriocarcinoma specimens was positive in CA IX staining. This result is consistent with the study of Donato *et al* ([@b28-ol-0-0-5745]), where choriocarcinoma tumors were predominately negative in CA IX. In contrast to the results published by Donato *et al* ([@b28-ol-0-0-5745]), the present study detected CA IX expression not only in teratomas and embryonal carcinomas, but also in seminomas and in yolk sac tumors. On the other hand we identified no CA IX expression in germ cell neoplasia *in situ*. GCNIS represents a precursor lesion for invasive TGCT of the adult testis ([@b29-ol-0-0-5745]). Thus, we may suppose that CA IX expression does not belong to early events in the pathogenesis of TGCTs. We also failed to detect any significant association between the CA IX expression and the patients/tumor characteristics. However, our data indicated the value of CA IX in the prognosis of progression-free survival, since CA IX expression in analyzed patients tumor specimens correlated with the significantly worse PFS. These findings are in agreement with previous reports on the prognostic value of CA IX in the wide variety of human carcinomas, including upper gastrointestinal cancer, breast cancer, ovarian and cervical cancer, nasopharyngeal cancer, lung and rectal cancer ([@b30-ol-0-0-5745]--[@b36-ol-0-0-5745]). The relationship between the CA IX expression and progression-free survival in TGCT patients was confirmed by the subgroup analysis of non-seminoma patients, patients with one or more metastatic site as well as patients with retroperitoneal lymph node metastases. Moreover, the analysis of patients without lung, brain and non-pulmonary visceral metastases showed a similar association. On the other hand, we did not observe any association between the CA IX expression and unfavorable outcome in patients with brain metastases, non-pulmonary visceral metastases and in patients with S-stage 3. It is therefore possible that the poor prognosis of these groups of patients is related to other pathways than that driven by hypoxia. Based on these findings, we propose that CA IX expression, mainly in patients with metastatic disease but without high-risk features (specifically, patients without brain and non-pulmonary visceral metastases and/or S-stage 3) may serve as prognostic marker of inferior outcome. This suggestion is also supported by the observation, that the hypoxic microenvironment plays a role in inferior outcome and chemoresistance due to increased burden of circulating tumor cells ([@b16-ol-0-0-5745]). Experimental data suggest that the tumor cells overexpress CA IX in order to maintain the intracellular pH and thus preserve their survival in hypoxia ([@b37-ol-0-0-5745]). The acidification of extracellular space mediated by this mechanism contributes to tumor cell invasion, development of metastases and therefore to worse progression-free survival ([@b38-ol-0-0-5745],[@b39-ol-0-0-5745]). The study has some limitations, including the relative under-representation of choriocarcinoma and yolk sac tumor and the selection of tissue samples into the tissue microarray. For this reason we performed whole tissue section immunohistochemical staining of several TGCT cases, and identified corresponding staining pattern with that in the tissue array. Notably, the TRIS-EDTA pretreatment of the slides considerably increased the sensitivity of CA IX expression detection in the studied tumor specimens.

In conclusion, the present translational study demonstrated significant overexpression of CA IX in TGCTs when compared to normal testicular tissue. We detected for the first time an association between CA IX expression in primary tumor tissue and worse progression-free survival in patients with TGCTs. Higher CA IX expression correlating with inferior outcome was found predominantly in patients with metastatic disease. These results suggest that CA IX expression may serve as an important predictive factor associated with disease recurrence and poor progression-free survival time in patients with advanced testicular cancer.
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![Immunohistochemical detection of CA IX expression in testicular germ cell tumors. (A) Seminoma showed focal moderate membrane CA IX positivity (brown). (B) Yolk sac tumor with focal strong cytoplasmic CA IX positivity. (C) Embryonal carcinoma with focal strong cytoplasmic CA IX positivity. (D) Mature teratoma with strong cytoplasmic CA IX positivity in epithelial component and negativity in mesenchymal component. Magnification, upper ×40, lower ×400. CA IX, carbonic anhydrase IX.](ol-13-04-2177-g00){#f1-ol-0-0-5745}

![Kaplan-Meier estimates of probabilities of progression-free survival according to CA IX expression in TGCT patients (n=228; HR, 0.57; 95% CI, 0.32--1.02; P=0.037). CA IX, carbonic anhydrase IX; TGCT, testicular germ cell tumors; PFS, progression free survival; HR, hazard ratio; CI, confidence interval.](ol-13-04-2177-g01){#f2-ol-0-0-5745}

![Kaplan-Meier estimates of probabilities of overall survival according to CA IX expression in TGCT patients (n=228; HR, 0.58; 95% CI, 0.29--1.16; P=0.088). CA IX, carbonic anhydrase IX; TGCT, testicular germ cell tumors; OS, overall survival; HR, hazard ratio; CI, confidence interval.](ol-13-04-2177-g02){#f3-ol-0-0-5745}

###### 

Patient characteristics (n=228).

  Characteristics                         No.                           \%
  --------------------------------------- ----------------------------- ------
  Age (years)                                                           
    Median (range)                        30 ([@b16-ol-0-0-5745]--67)   
  Histology                                                             
    Seminoma                              44                            19.3
    Non-seminoma                          184                           80.7
  IGCCCG risk group prognosis                                           
    Good                                  173                           75.8
    Intermediate                          25                            11.0
    Poor                                  30                            13.2
  Sites of metastases                                                   
    Retroperitoneum                       159                           69.7
    Mediastinum                           23                            10.1
    Lungs                                 52                            22.8
    Liver                                 12                            5.3
    Brain                                 3                             1.3
    Other                                 11                            4.8
    Non-pulmonary visceral metastases     16                            7.0
  No. of metastatic sites                                               
    0                                     64                            28.1
    1                                     98                            43.0
    2                                     34                            14.9
    \>3                                   32                            14.0
  Mean (range) of pretreatments markers                                 
    AFP mIU/ml                            1168.0 (0.0--60570.0)         
    -HCG IU/ml                            15980.0 (0.0--929000.0)       
    LDH (mkat/l)                          11.0 (0.0--88.6)              

-HCG, -human chorionic gonadotropin; AFP, α-fetoprotein; LDH, lactate dehydrogenase; IGCCCG, international germ cell consensus classification group.

###### 

CA IX expression in different histologic subtypes of the primary germ cell tumors (n=205).

                                       CA IX expression                          
  ----------------------------- ------ ------------------ -------- ----- ------- ---------
  Healthy testis                107    107                100.0      0     0.0   N/A
  Testicular germ cell tumors   205    143                  69.8   62    30.2    \<0.001
    Seminoma                      75     58                 77.3   17    22.7    \<0.001
    Embryonal carcinoma         118    104                  88.1   14    11.9    \<0.001
    Yolc sac tumor                36     28                 77.8     8   22.2    \<0.001
    Choriocarcinoma               13     12                 92.3     1     7.7   0.11
    Teratoma                      59     36                 61.0   23    39.0    \<0.001
    GCNIS                         76     76               100.0      0     0.0   N/A

GCNIS, germ cell neoplasia *in situ*; CA IX, carbonic anhydrase IX.

###### 

Composition of mixed testicular germ cell tumors (n=76).

  No. of patients   Histological subtype
  ----------------- ----------------------
  22                EC/TER
  15                EC/SEM
    6               EC/YST/TER
    6               YST/TER
    5               EC/YST
    4               EC/ChC/TER
    4               SEM/TER
    3               EC/SEM/TER
    3               EC/ChC
    3               YST/ChC/TER
    1               EC/SEM/YST
    1               EC/SEM/YST/TER
    1               SEM/YST
    1               EC/SEM/ChC
    1               YST/ChC

EC, embryonal carcinoma; SEM, seminoma; YST, yolk sac tumour; ChC, choriocarcinoma; TER, teratoma.

###### 

Patient characteristics according to the CA IX expression in the primary tumors (n=205).

                                      CA IX expression                                 
  ----------------------------------- ------------------ ------ -------- ----- ------- -------
  All patients                        205                143      69.8   62    30.2    N/A
  Histology                                                                            
    Seminoma                            40                 28     70.0   12    30.0    0.567
    Non-seminoma                      165                115      69.7   50    30.3    
  IGCCCG risk group                                                                    
    Good/Intermediate prognosis       180                127      70.6   53    29.4    0.325
    Poor prognosis                      25                 16     64.0     9   36.0    
  Number of metastatic sites                                                           
    0                                   58                 38     65.5   20    34.5    0.841
    ≥1                                147                105      71.4   42    28.6    
  Retroperitoneal LN metastases                                                        
    Absent                              62                 40     64.5   22    35.5    0.892
    Present                           143                103      72.0   40    28.0    
  Mediastinal LN metastases                                                            
    Absent                            187                133      71.1   54    28.9    0.136
    Present                             18                 10     55.6     8   44.4    
  Lung metastases                                                                      
    Absent                            160                114      71.3   46    28.8    0.242
    Present                             45                 29     64.4   16    35.6    
  Liver                                                                                
    Absent                            194                136      70.1   58    29.9    0.438
    Present                             11                 7      63.6     4   36.4    
  Brain                                                                                
    Absent                            204                142      69.6   62    30.4    1.000
    Present                             1                  1    100.0      0     0.0   
  Non-pulmonary visceral metastases                                                    
    Absent                            191                134      70.2   57    29.8    0.423
    Present                             14                 9      64.3     5   35.7    
  S-stage                                                                              
    0-II                              186                132      71.0   54    29.0    0.178
    III                                 19                 11     57.9     8   42.1    

CA IX, carbonic anhydrase IX; IGCCCG, international germ cell consensus classification group; LN, lymph node.

###### 

Multivariate analysis of the potential prognostic value of CA IX.

                                                           Progression free survival   Overall survival                           
  -------------------------------------------------------- --------------------------- ------------------ ----------------------- ---------
  CA IX expression in primary tumor high vs. low           1.650 (0.963--2.826)          0.068            1.613 (0.844--3.080)      0.148
  IGCCCG risk group poor vs. good/intermediate prognosis   5.260 (3.005--9.209)        \<0.001            8.282 (4.286--16.005)   \<0.001

CA IX, carbonic anhydrase IX; IGCCCG, international germ cell consensus classification group; HR, hazard ratio; CI, confidence interval.

###### 

Prognostic value of CA IX as an independent indicator in different patient subgroups.

  Variable                            No.   PFS HR (95% CI)      P-value     OS HR (95% CI)       P-value
  ----------------------------------- ----- -------------------- ----------- -------------------- ---------
  Histology                                                                                       
    Seminoma                          44    2.46 (0.45--13.48)   0.396       1.00 (0.09--11.00)   0.997
    Non-seminoma                      184   0.47 (0.25--0.87)    **0.006**   0.54 (0.26--1.12)    0.067
  IGCCCG group                                                                                    
    Good prognosis                    173   0.68 (0.29--1.62)    0.342       0.56 (0.16--1.94)    0.305
    Intermediate prognosis            25    0.49 (0.14--1.72)    0.258       0.88 (0.22--3.53)    0.857
    Poor prognosis                    30    0.73 (0.29--1.88)    0.499       0.73 (0.27--1.99)    0.518
  Number of metastatic sites                                                                      
    0                                 64    0.79 (0.14--4.46)    0.756       0.43 (0.05--3.53)    0.317
    ≥1                                164   0.50 (0.27--0.94)    **0.013**   0.56 (0.27--1.19)    0.099
  Reroperitoneal LN metastases                                                                    
    Present                           159   0.49 (0.26--0.94)    **0.014**   0.58 (0.27--1.24)    0.120
    Absent                            69    0.65 (0.14--3.05)    0.536       0.33 (0.05--2.11)    0.141
  Mediastinal LN metastases                                                                       
    Present                           23    0.43 (0.13--1.41)    0.161       0.48 (0.12--1.94)    0.303
    Absent                            205   0.68 (0.35--1.31)    0.210       0.60 (0.26--1.37)    0.1785
  Lung metastases                                                                                 
    Present                           52    0.82 (0.35--1.92)    0.636       0.69 (0.28--1.68)    0.379
    Absent                            176   0.48 (0.22--1.05)    **0.035**   0.50 (0.17--1.49)    0.162
  Liver metastases                                                                                
    Present                           12    0.30 (0.05--2.01)    0.115       0.32 (0.05--2.05)    0.130
    Absent                            216   0.60 (0.33--1.12)    0.076       0.62 (0.29--1.32)    0.176
  Brain metastases                                                                                
    Present                           3     NA                   NA          NA                   NA
    Absent                            225   0.54 (0.30--0.98)    **0.024**   0.53 (0.26--1.08)    0.052
  Non-pulmonary visceral metastases                                                               
    Present                           16    0.52 (0.10--2.64)    0.355       0.53 (0.11--2.68)    0.377
    Absent                            217   0.56 (0.30--1.04)    **0.041**   0.55 (0.25--1.21)    0.099
  S-stage                                                                                         
    0-II                              206   0.57 (0.29--1.12)    0.070       0.61 (0.26--1.45)    0.224
    III                               22    0.62 (0.20--1.91)    0.368       0.51 (0.16--1.67)    0.219

P-values in bold indicate statistically significant differences. CA IX, carbonic anhydrase IX; IGCCCG, international germ cell consensus classification group; HR, hazard ratio; CI, confidence interval; PFS, progression free survival; OS, overall survival; LN, lymph node.

[^1]: Contributed equally
